Neutralization escape by SARS-CoV-2 Omicron subvariant BA.2.86

The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) variant BA.2.86 has over 30 mutations in spike compared with BA.2 and XBB.1.5, which raised the possibility that BA.2.86 might evade neutralizing antibodies (NAbs) induced by vaccination or infection. In this study, we show that NAb ti...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2023-11, Vol.41 (47), p.6904-6909
Main Authors: Lasrado, Ninaad, Collier, Ai-ris Y., Hachmann, Nicole P., Miller, Jessica, Rowe, Marjorie, Schonberg, Eleanor D., Rodrigues, Stefanie L., LaPiana, Austin, Patio, Robert C., Anand, Trisha, Fisher, Jana, Mazurek, Camille R., Guan, Ruoran, Wagh, Kshitij, Theiler, James, Korber, Bette T., Barouch, Dan H.
Format: Article
Language:English
Subjects:
60 APPLIED LIFE SCIENCES
Antibodies
Antibodies, Neutralizing
Antibodies, Viral
BA.2.86
biological science
Consortia
Coronaviruses
COVID-19
COVID-19 vaccines
Genomes
Hispanic Americans
Humans
immune evasion
Immunization, Secondary
Infections
mRNA
Neutralization
Neutralizing antibody
Pathogens
Respiratory diseases
SARS-CoV-2
SARS-CoV-2 - genetics
Severe acute respiratory syndrome coronavirus 2
Vaccination
Vaccine
vaccines
variant
Viral diseases
Viruses
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) variant BA.2.86 has over 30 mutations in spike compared with BA.2 and XBB.1.5, which raised the possibility that BA.2.86 might evade neutralizing antibodies (NAbs) induced by vaccination or infection. In this study, we show that NAb titers are substantially lower to BA.2.86 compared with BA.2 but are similar or slightly higher than to other current circulating variants, including XBB.1.5, EG.5.1, and FL.1.5.1. Moreover, NAb titers against all these variants were higher in vaccinated individuals with a history of XBB.1.5 infection compared with vaccinated individuals with no history of XBB.1.5 infection, suggesting the potential utility of the monovalent XBB.1.5 mRNA boosters.
ISSN:0264-410X
1873-2518
1873-2518
DOI:10.1016/j.vaccine.2023.10.051